Literature DB >> 1385727

Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK.

J N Liu1, V Gurewich.   

Abstract

In a previous study, it was shown that fibrin fragment E-2 selectively promotes the activation of plasminogen by pro-urokinase (pro-UK) [Liu, J., & Gurewich, V. (1991) J. Clin. Invest. 88, 2012-2017]. In this study, the kinetics of this promotion by fragment E-2 was studied. Alanine-158-rpro-UK (A-pro-UK), a recombinant plasmin-resistant mutant, was used in order to avoid interference by UK generation during the reaction. In some experiments, pro-UK was substituted in order to validate the mutant as a surrogate. In the presence of a range of concentrations (0-20 microM) of fragment E-2, a linear promotion of the catalytic efficiency of A-pro-UK against native Glu-plasminogen was seen which was 245.5-fold at the highest concentration of fragment E-2 and 450-fold at the highest ratio of E-2/plasminogen used. The promotion was largely a function of an increase in kcat, since fragment E-2 induced a less than 10-fold reduction in KM (8.50-1.40 microM). In contrast to this ligand, epsilon-aminocaproic acid (EACA) induced a biphasic promotion of the activation of Glu-plasminogen which was only 18-fold at maximum. Fragment E-2 did not promote the activation of Lys-plasminogen, but the catalytic efficiency of A-pro-UK was 19.7-fold greater against the open Lys-form than against the closed Glu- form of plasminogen. Fragment E-2 had no effect on the amidolytic activity of A-pro-UK or pro-UK, suggesting that the promotion of their activities was indirect and related to a fragment E-2-induced conformational change in Glu-plasminogen.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385727     DOI: 10.1021/bi00142a021

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

Review 1.  Molecular basis of thrombolytic therapy.

Authors:  H R Lijnen; D Collen
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

2.  Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.

Authors:  R Pannell; S Li; V Gurewich
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

Review 3.  Targeting antioxidant and antithrombotic biotherapeutics to endothelium.

Authors:  Ronald Carnemolla; Vladimir V Shuvaev; Vladimir R Muzykantov
Journal:  Semin Thromb Hemost       Date:  2010-05-20       Impact factor: 4.180

4.  Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.

Authors:  Sergei Zaitsev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Oscar A Marcos-Contreras; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2010-04-21       Impact factor: 22.113

Review 5.  Targeted delivery of therapeutics to endothelium.

Authors:  Eric Simone; Bi-Sen Ding; Vladimir Muzykantov
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

6.  Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.

Authors:  Juan-Carlos Murciano; Abd Al-Roof Higazi; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2009-07-16       Impact factor: 9.776

7.  Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke.

Authors:  Simone Tomasi; Paolo Sarmientos; Giada Giorda; Victor Gurewich; Alessandro Vercelli
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

8.  Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK.

Authors:  Ralph Pannell; Shelley Li; Victor Gurewich
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 9.  Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement.

Authors:  Victor Gurewich
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

10.  The use of thromboelastography to assess post-operative changes in coagulation and predict graft function in renal transplantation.

Authors:  Carson B Walker; Hunter B Moore; Trevor L Nydam; Alexander C Schulick; Hillary Yaffe; James J Pomposelli; Michael Wachs; Thomas Bak; Kendra Conzen; Megan Adams; Thomas Pshak; Rashikh Choudhury; Michael P Chapman; Elizabeth A Pomfret; Peter Kennealey
Journal:  Am J Surg       Date:  2020-08-27       Impact factor: 2.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.